SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date, amended upper-limb data and recent commercial-launch job postings. Many expect approval and anticipate short covering, while others stress that hiring and FDA rare-disease messaging are not proof of a favorable decision and point to the prior setbacks and remaining efficacy questions.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a 52-week high has traders positioning around the expected Q3 earnings report, with BRIUMVIs sales growth supporting optimism. Buyout rumors and heavy short interest are fueling squeeze speculation, though some traders see earnings expectationsnot a confirmed acquisitionas the main driver.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios reported FDA approval of a competing RRP treatment has fueled debate over the threat to Precigens PAPZIMEOS and whether the selloff is an overreaction; traders disagree on the therapies relative advantages and Precigens commercial head start. Attention is also turning to upcoming PRGN-2009 clinical data and a Q3 business update.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure after a steep decline, with traders focused on analyst price-target cuts and uncertainty ahead of its earnings report, as well as concerns about digital-ad growth. Bulls argue the selloff is disconnected from the companys profitability and growth, while bears warn of more downside if results or guidance disappoint; some also point to broader tech-market weakness.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL leukemia trial reached its prespecified 80th death event, triggering final analysis and putting the GPS survival readout at the center of discussion. Traders are divided between optimism about a strong result and concerns about the control arm and trial design, while shares have come under pressure ahead of the binary catalyst.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicares post-TDAPA reimbursement contribution for DefenCath could decline through 2027 is driving the sharp selloff and debate over future revenue. Some traders view the comments as a serious pricing risk, while others argue DaVitas estimates are preliminary and point to CMSs more favorable payment assumptions; several describe the decline as an overreaction.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure amid a semiconductor and tech selloff, as traders question whether heavy AI infrastructure spending will generate adequate returns; weak Intel guidance and concerns about Amazons elevated capex are cited as contributing pressures. The community is divided between expecting a deeper unwind in the AI trade and seeing oversold conditions and technical support as possible grounds for a bounce.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp Nasdaq selloff has put QQQ in correction territory, with traders linking the pressure to weakness across technology and AI-related stocks, worries about returns on heavy AI spending, and rising-rate concerns. The community is split between bears expecting further losses and dip-buyers anticipating a relief bounce or short squeeze.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas strong quarterly results and raised outlook, alongside expectations that AI agents will increase demand for identity security, fueled a sharp rally. Traders are now debating whether the growth outlook justifies the valuation, with some taking profits or positioning for a pullback.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Lines stronger-than-expected third-quarter results and raised full-year outlook sparked a sharp rally, with traders debating whether heavy short interest could amplify the move. The reaction is mixed: some see evidence of a turnaround, while others point to profit-taking, fuel-cost pressures and lingering concerns about bookings and yields.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Exelixis (EXEL) Surpasses Q3 Earnings and Revenue Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of +5.62% and +0.86%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Equity

Under the FDA’s new draft guidance, companies can file one application that covers several versions of the same gene-editing treatment, as long as each version aims to make the same kind of genetic correction.


Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates

Biogen (BIIB) delivered earnings and revenue surprises of +27.18% and +8.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now

BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.

Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms

The trades put some of Ark's better-known holdings on the sell side, including AMD, Alphabet, and SpaceX, while its genomics-focused ARK Genomic Revolution ETF continued to add to biotech companies.

Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?

Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares

Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.


CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?

CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.

Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?

NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.

FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Companies with modular gene editing platforms stand to benefit most, including Prime Medicine’s prime-editing system and lipid-nanoparticle delivery, if the draft is adopted.</li><li>The draft guidance is now open for public comment, which will later be reviewed by the FDA before it decides whether to adopt it.&nbsp;</li><li>Earlier this month, the company announced it had dosed the first patient in a global Phase 1/2 trial of PM577a for Wilson disease—the first known use of prime editing therapy inside a living patient.</li></ul>Shares of gene-editing companies, including Prime Medicine (PRME), rallied on Wednesday after the U.S. Food and Drug Administration issued draft guidance designed to speed personalized treatment for rare genetic diseases.Under the FDA’s new draft guidance, companies can file one application that covers several versions of the same gene-editing treatment, as long as each version aims to make the same kind of genetic correction. Once clinical results support the core approach, new versions that stay within set limits can be added later using mainly lab tests instead of full new patient trials. The guidance applies to gene-editing therapies for rare diseases caused by a single known genetic fault.Companies with modular gene editing platforms stand to benefit most, including Prime Medicine’s prime-editing system and lipid-nanoparticle delivery, if the draft is adopted. The draft guidance is now open for public comment, which will be later reviewed by the FDA before it decides whether to adopt it.Shares of Prime Medicine were up 20% at the time of writing, while Beam Therapeutics traded 14% higher and Intellia Therapeutics (NTLA) and Editas Medicine (EDIT) climbed 6-11%. CRISPR Therapeutics (CRSP) posted more modest gains of 4%.<h2 class="st-heading-2">Why PRME Is Outperforming Peers</h2>Prime clocked larger gains than its peers as it builds on company-specific updates. Earlier this month, the company announced it had dosed the first patient in a global Phase 1/2 trial of PM577a for Wilson disease—the first known use of prime editing therapy inside a living patient. The FDA also granted the program Rare Pediatric Disease designation. Initial clinical data from the Wilson disease study are expected in 2027.The company also recently received the FDA’s clearance to start human trials of an alpha-1 antitrypsin deficiency candidate.<h2 class="st-heading-2">How Did PRME Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$PRME" data-symbol-id="PRME" href="https://stocktwits.com/symbol/PRME" target="_blank">PRME stock</a> jumped from 'neutral' to 'extremely bullish' territory over the past 24 hours, while message volume increased from 'low' to 'extremely high' levels.A Stocktwits user noted that big pharma company Bristol Myers Squibb is invested in Prime. The user is referring to a collaboration deal between BMY and Prime inked in Sept. 2024 under which Prime received $110 million upfront, including a $55 million equity investment. The company is eligible for more than $3.5 billion in potential milestones under the deal.<stembedurl>https://stocktwits.com/Cello69/message/667555201</stembedurl>Another user, however, warned of upcoming dilution.<stembedurl>https://stocktwits.com/Regard994/message/667538755</stembedurl>PRME stock has gained 51% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/uber-stock-hits-fresh-52-week-low-ahead-of-earnings-as-robotaxi-fears-linger/cZU9V5OR9GK">UBER Stock Hits Fresh 52-Week Low Ahead Of Earnings As Robotaxi Fears Linger</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artwork of DNA Editing. Source: Getty Images

Under the FDA’s new draft guidance, companies can file one application that covers several versions of the same gene-editing treatment, as long as each version aims to make the same kind of genetic correction.

Beam Therapeutics Inc

CRISPR Therapeutics AG

Editas Medicine Inc

Prime Medicine Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

NTLA News